November 21st 2016

The first data for guselkumab in patients with active psoriatic arthritis, from a 24-week Phase 2a study, were presented at the ACR/ARHP Annual Meeting in November 2016

Coming soon: Dr Kenneth Gordon will consider the potential for the IL-23 pathway in the treatment of psoriatic arthritis.